Board Change

Sensyne Health plc

Board Change

Oxford, UK; 24 October 2018: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announces that Professor Sir John Bell has stepped down as Chairman of the Board to avoid any potential conflicts of interest that may arise from his role advising the UK Government on the Life Sciences Industrial Strategy. In this role, Professor Bell authored the Life Sciences Strategy Document and has been instrumental in delivering a programme defined in the report to grow the life sciences sector in the UK.

Charles Swingland will replace Professor Bell as Chairman on an interim basis before returning to his Non-Executive Director position when a search for a permanent Chairman has concluded.

Building on its unique business model and proven acceptance by both the UK Government and the NHS, Sensyne Health is actively exploring scaling up its business further including responding to any government-led initiatives involving NHS datasets.

Commenting on today's announcement, Lord (Paul) Drayson, Chief Executive Officer of Sensyne Health plc, said: "On behalf of the Board, I thank John for his significant contribution to this company and his leadership of the Board through the successful IPO. Sensyne is committed to transparency and good corporate governance so we understand his obligation to step away from Sensyne as we pursue our commitment to improve patient health, medical practices and NHS healthcare costs and efficiencies through the analysis of both larger volumes of anonymised UK patient data and additional healthcare data sets."

Professor Sir John Bell said: "I have thoroughly enjoyed my time at Sensyne, supporting the business through its initial development and recent successes. Now is the right time to relinquish my Board responsibilities to avoid any potential conflicts of interest."

-ENDS-

For more information please contact:

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology'.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com